Beta variant,also known as lineage B.1.351, is a variant of SARS-CoV-2, the virus that causes COVID-19. One of several SARS-CoV-2 variants believed to be of particular importance, it was first detected in the Nelson Mandela Bay metropolitan area of the Eastern Cape province of South Africa in October 2020, which was reported by the country's health department on 18 December 2020. Phylogeographic analysis suggests this variant emerged in the Nelson Mandela Bay area in July or August 2020.
The World Health Organization labelled the variant as Beta variant, not to replace the scientific name but as a name for the public to commonly refer to.The WHO considers it to be a variant of concern.
Footnote: 1Presented in parent lineage B.1.
Source: Tegally et al. (2020) , supplementary Fig S8
There are three mutations of particular interest in the spike region of the lineage B.1.351 genome:
and a further five spike mutations which have so far generated less concern:
Away from the spike region, it also carries: K1655N, SGF 3675-3677 deletion, P71L, and T205I.
Scientists noted that the variant is able to attach more easily to human cells because of three mutations in the receptor-binding domain (RBD) in the spike glycoprotein of the virus: N501Y(a change from asparagine (N) to tyrosine (Y) in amino-acid position 501), K417N, and E484K. Two of these mutations, E484K and N501Y, are within the receptor-binding motif (RBM) of the receptor-binding domain (RBD).
The N501Y mutation has also been detected in the United Kingdom.Two mutations found in the Beta variant, E484K and K417N, are not found in Alpha variant. Also, Beta does not have the 69-70del mutation found in the other variant.
On 4 January 2021, UK newspaper The Telegraph reported that Oxford immunologist Sir John Bell believed there was "a big question mark" over the new South African variant's potential resistance to COVID-19 vaccines, raising fears that vaccines might not work as effectively on that variant strain.The same day Shabir Madhi, professor of vaccinology at the University of the Witwatersrand, commented to CBS News that "it's not a given" that the new Beta variant (501.V2 variant) would be able to evade the vaccines, but that it should be considered that they "might not have the full efficacy". The additional mutations to the spike protein in Beta were raised as a concerning factor by Simon Clarke, an associate professor in cellular microbiology at the University of Reading, in that they "may make the virus less susceptible to the immune response triggered by the vaccines". Lawrence Young, a virologist at Warwick University, also noted that the variant's multiple spike mutations "could lead to some escape from immune protection".
The E484K amino acid change, a receptor-binding-domain (RBD) mutation, was reported to be "associated with escape from neutralising antibodies" which could adversely affect the efficacy of spike protein-dependent COVID vaccines.The E484K spike mutation was linked to a case of reinfection with the Beta variant of SARS-CoV-2 in Brazil, believed by researchers to be the first such case of reinfection involving this mutation. The possibility of an alteration in antigenicity was referred to as an "escape mutation" from a monoclonal antibody with the capability of neutralizing the spike protein variants of SARS-CoV-2. This suggests that existing vaccines can and should be updated to counter the new strains without recourse to phased trials.
In January, Johnson & Johnson, which held trials for its Janssen (Ad26.COV2.S) vaccine in South Africa, reported the level of protection against moderate to severe COVID-19 infection was 72% in the United States, but 64% in South Africa.
On 17 February 2021, Pfizer announced that neutralisation activity was reduced by two thirds for the Beta variant, whilst refraining from making claims about the efficacy of the vaccine in preventing illness as a result of this variant.
On 16 March 2021, The South African Health Products Regulatory Authority (SAHPRA) approved the Pfizer-BioNTech vaccine (BNT162b2) for section 21 Emergency Use Authorisation.
On 1 April 2021, an update on a South African vaccine trial stated that the vaccine was 100% effective so far (i.e., vaccinated participants saw no cases), with six of nine infections in the placebo control group being the Beta variant (lineage B.1.351).However, nine days later, an Israeli study found that the variant was present even in people who had received both shots of the vaccine, its prevalence a disproportionate, eight-fold increase amongst vaccinated individuals in comparison to wild strains.
On 5 May 2021, a letter summarizing results from the Qatar National Study Group for COVID-19 Vaccination showed 75% effectiveness against infection, with zero cases of severe disease.
On 6 February 2021, The Financial Times reported that provisional trial data from a study undertaken by South Africa's University of the Witwatersrand in conjunction with Oxford University demonstrated reduced efficacy of the Oxford–AstraZeneca COVID-19 vaccine (AZD1222) against the Beta variant. The study found that in a sample size of 2,000 the AZD1222 vaccine afforded only "minimal protection" in all but the most severe cases of COVID-19.
On 7 February 2021, the South African government suspended the planned deployment of around 1 million doses of the vaccine whilst they examined the data and awaited advice on how to proceed.The South African government subsequently cancelled the use of the vaccine, selling its supply to other African countries, and switched its vaccination program to use the Janssen COVID-19 vaccine.
In July 2021, following increased incidence of Beta in France, the United Kingdom - a major user of the AstraZeneca vaccine - placed additional restrictions on people travelling to the UK from France. However, the incidence in France is in its Indian Ocean territory of La Réunion,as pointed out by French politician and doctor Veronique Trillet-Lenoir.
Other African countries have begun the roll out BBIBP-CorV from Sinopharm, with Morocco, Egypt, The Seychelles and Zimbabwe starting the mass rollout.So far, the vaccine has proven resistant to the Beta variant, as demonstrated in Zimbabwe. On 2 February 2021, a preprint paper announced that neutralisation activity was reduced by 1.6 fold for the Beta variant.
In February, Moderna reported that the current vaccine (mRNA-1273) produced only one sixth of the antibodies in response to the South African variant compared with the original virus. They have launched a trial of a new vaccine to tackle the Beta variant.
The South African Health Products Regulatory Authority (SAHPRA) has confirmed that it has received documentation for the vaccine developed by the Gamaleya Institute in Russia.
Sputnik V (Gam-COVID-Vac) is one of three Covid vaccines worldwide with an efficacy higher than 90% in symptomatic cases. It was found to be slightly less effective however it worked better than its rivals. A three fold reduction in VNA was found against the beta variant.
CoronaVac is yet to be approved for use by the South African Health Products Authority (SAHPRA).So far, Sinovac has offered to supply South Africa with 5 million doses of the vaccine.
Covaxin has been found to be effective against the beta variant although with a three fold reduction in neutralization.
The CoviVac vaccine Information has not been delivered to the South African government yet.
The EpiVacCorona vaccine Information has not been delivered to the South African government yet.
The ZF2001 vaccine Information is in the process of being delivered to the South African government.
A study on the NVX-CoV2373 Novavax vaccine showed 60% efficacy (for HIV-negative participants) in South Africa, compared to 90% efficacy in Britain.
The BioVac Institute, a state-backed South African vaccine company, plans to use a deal it won to manufacture coronavirus vaccines. The contract with American based ImmunityBio Inc is currently conducting phase 1 vaccine trials with their hAd5 vaccine in the United States and South Africa.
ImmunityBio and BioVac plan to distribute the vaccines throughout South Africa and Africa.
Researchers and officials reported that the prevalence of the variant was higher among young people with no underlying health conditions, and more frequently causes serious illness in such cases than other variants.The South African health department also indicated that the variant may be driving the second wave of the COVID-19 pandemic in the country, as the variant spreads faster than other earlier variants of the virus.
|Cases by country (Updated as of 21 July 2021) GISAID|
|Country||Confirmed cases||Collection date|
|Angola||401||22 April 2021|
|Argentina||1||24 April 2021|
|Aruba||4||10 April 2021|
|Australia||73||28 June 2021|
|Austria||260||8 June 2021|
|Bahrain||1||9 April 2021|
|Bangladesh||56||16 June 2021|
|Belgium||1,075||14 June 2021|
|Bosnia and Herzegovina||1||11 February 2021|
|Botswana||342||27 June 2021|
|Brazil||6||5 April 2021|
|Brunei||1||20 January 2021|
|Bulgaria||2||9 June 2021|
|Cambodia||1||31 May 2021|
|Cameroon||9||1 March 2021|
|Canada||860||21 June 2021|
|Chile||4||22 May 2021|
|China||89||4 June 2021|
|Colombia||1||13 April 2021|
|Costa Rica||12||4 May 2021|
|Cote d'Ivoire||1||6 March 2021|
|Czech Republic||71||10 June 2021|
|Democratic Republic of the Congo||30||20 April 2021|
|Denmark||121||29 June 2021|
|Djibouti||22||9 April 2021|
|Equatorial Guinea||43||1 April 2021|
|Estonia||37||23 April 2021|
|Eswatini||26||23 March 2021|
|Finland||1,123||21 May 2021|
|France||2,149||23 June 2021|
|French Guiana||2||7 April 2021|
|Gabon||4||21 February 2021|
|Georgia||1||23 May 2021|
|Germany||2,231||19 June 2021|
|Ghana||17||8 April 2021|
|Greece||19||29 April 2021|
|Guadeloupe||4||25 May 2021|
|Guam||3||28 April 2021|
|Guinea Bissau||1||1 February 2021|
|India||208||14 June 2021|
|Indonesia||10||2 June 2021|
|Iran||2||3 April 2021|
|Iraq||1||26 February 2021|
|Ireland||69||19 April 2021|
|Israel||240||28 May 2021|
|Italy||69||1 June 2021|
|Japan||89||13 June 2021|
|Jordan||2||18 April 2021|
|Kenya||178||31 May 2021|
|Kuwait||1||21 June 2021|
|Latvia||9||13 May 2021|
|Lesotho||14||18 January 2021|
|Lithuania||11||9 April 2021|
|Luxembourg||744||22 May 2021|
|Malawi||312||16 April 2021|
|Malaysia||161||10 June 2021|
|Malta||3||1 June 2021|
|Martinique||2||28 April 2021|
|Mauritius||7||12 March 2021|
|Mayotte||32||31 January 2021|
|Mexico||20||16 May 2021|
|Mozambique||328||22 April 2021|
|Netherlands||693||27 May 2021|
|New Zealand||31||25 June 2021|
|North Macedonia||1||10 March 2021|
|Norway||362||11 June 2021|
|Pakistan||35||5 June 2021|
|Panama||2||12 January 2021|
|Philippines||1,213||8 April 2021|
|Poland||45||7 June 2021|
|Portugal||99||2 June 2021|
|Qatar||650||18 May 2021|
|Reunion||400||19 June 2021|
|Romania||7||26 May 2021|
|Russia||23||12 June 2021|
|Rwanda||39||15 June 2021|
|Saudi Arabia||3||15 April 2021|
|Singapore||100||25 June 2021|
|Sint Maarten||1||24 March 2021|
|Slovakia||31||27 May 2021|
|Slovenia||31||6 April 2021|
|South Africa||6,154||21 June 2021|
|South Korea||19||17 April 2021|
|South Sudan||3||24 April 2021|
|Spain||588||18 June 2021|
|Sri Lanka||4||26 March 2021|
|Suriname||5||31 March 2021|
|Sweden||2,322||17 June 2021|
|Switzerland||225||22 June 2021|
|Taiwan||3||26 April 2021|
|Thailand||40||25 May 2021|
|Togo||2||5 February 2021|
|Tunisia||1||24 April 2021|
|Turkey||912||24 May 2021|
|Uganda||13||2 April 2021|
|United Arab Emirates||6||27 April 2021|
|United Kingdom||812||24 June 2021|
|USA||2,454||28 June 2021|
|Zambia||161||28 April 2021|
|Zimbabwe||331||26 February 2021|
|World (103 countries)||Total: 28,380||Total as of 21 July 2021|
A genomics team lead by the KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP) at the University of KwaZulu-Natal discovered the new variant. [ better source needed ]It was uncovered by whole genome sequencing. Several genomic sequences from this lineage were submitted to the GISAID sequence database.
On 23 December, UK health minister Matt Hancock announced that two people who had travelled from South Africa to the UK were infected with the Beta variant (501.V2 variant).On 28 December, the variant had been detected in two people in Switzerland and in one in Finland. On 29 December, the strain had been detected in a visitor from South Africa to Japan, and in one overseas traveller to Queensland, Australia. On 30 December the variant was detected in Zambia. On 31 December, it was also detected in France, in a passenger returning from South Africa. On 2 January 2021, the first case of this variant was detected in South Korea. Austria reported their first case of this variant, along with four cases of the Alpha variant on 4 January. The Republic of Botswana also detected their first case on 4 January. The People's Republic of China reported the first case of this variant in southern Guangdong province on 6 January.
On 8 January 2021, the Republic of Ireland reported the detection of 3 cases, all linked to travel from South Africa.On the same day a case of reinfection with the new variant by a woman who had had COVID-19 was reported from Brazil, the first such reinfection reported in the world. Canada reported the first case of this variant in Alberta on 9 January, and Israel reported four cases, all of which were imported in people travelling from South Africa. New Zealand reported the first case of this variant on 10 January. On 12 January, Germany reported the detection of the mutation in six people from three different households. The same day, it was reported that the United Kingdom had a total of 29 cases, two of which were previously reported. The following day, Belgium reported the first case in a person from West Flanders with no travel history, Israel reported four further cases, and Taiwan reported the first case in a Swazi man in his 30s who had tested positive for COVID-19 on 1 January.
On 14 January, Germany detected a further caseand the following day, Canada reported a second case of the mutation which was detected in the Canadian province of British Columbia. A further case was reported in Germany the same day. Denmark and Réunion reported their first cases on 16 January as Israel discovered a further four cases. On 17 January, Israel reported another four cases bringing their total number of cases of this variant to 20. Two further cases were reported in The Netherlands on 18 January bringing the country's total to three. Ghana reported its first case of the variant on 19 January. On 23 January, Panama detected its first case of the strain in a person from Zimbabwe, who had travelled from South Africa. Also on 23 January, Belgium reported at least 15 cases of the variant in Ostend, while 6 cases were confirmed in the Comoros. On 26 January, the Republic of Ireland reported the detection of 6 further cases. The United States reported its first cases of the variant on 28 January 2021, in the state of South Carolina. On 27 January, Israel reported 3 more cases which were the first cases of the variant from samples that were collected in the community randomly, without knowing the source of infection. Preliminary data reported by Africa CDC on 29 January indicated that the variant had reached Ghana. On 31 January, Israel reported its first case of reinfection with the new variant by a man who returned from Turkey.
On 1 February 2021, the United Kingdom Secretary of State for Health and Social Care reported the random detection of 11 cases of the variant where there was no connection to international travel.The same day, the Canadian province of Ontario reported the first case of the variant in the Peel Region, with a similar absence of travel history and no contact with anyone who had recently been abroad. On 8 February, the Republic of Ireland reported the detection of 2 further cases.
On 8 February 2021, Austria detected the greatest outbreak of Beta variant in Europe so far. A total of 293 confirmed cases and 200 suspected cases have been identified through sequencing, most of them will be confirmed in all probability. All of the cases were found in the Tirol region, where nearly 9% of the positive PCR tests were identified as the Beta variant by sequencing.The active cases were estimated at around 140. After a week of public discussion and political pressure about a possible quarantine of Tirol, the government of Austria abstained from isolating the areas of concern, instead making a formal plea to reduce movement in and out of the region and go for testing after visiting Tirol. Tirolean officials stated their intention to relax the lockdown rules in Tirol in keeping with the rest of Austria.
On 22 February, the Israeli Health Ministry stated that the variant had been genetically sequenced in just under 1% of 3,000 community samples.Later on, Israel reported a total of 444 cases of the variant, making it the highest infection rate in the world outside South Africa. On 25 February, the Republic of Ireland reported the detection of 4 further cases. By late February, Turkey had 49 cases of the Beta variant.
On 3 March 2021, the Philippines confirmed its first 6 new cases of the South African variant, with 3 patients from Pasay with no travel history, and 3 with travel histories from Qatar and UAE.On 5 March 2021, Romania reported its first two cases of the South African variant, coming from two patients in Bucharest and Pitești.
On 23 March 2021, Lithuania confirmed its first 2 new cases of the South African strain, 1 in Kaunas county and 1 in Vilnius. There are 10 more suspected cases of it. The infected people said, that they didn't travel anywhere.On 26 March there were 3 more cases confirmed, which means that virus is successfully spreading inside.
On 1 April 2021, Malaysia detected its first cases of South African variant. The health ministry reported two cases believed to originate from the Jalan Lima cluster, involving an employee based at the Kuala Lumpur International Airport (KLIA), with other reported cases sparsely detected within Selangor.As of 1 April, a total of nine cases involving the variant is reported. By 2 May, a total of 48 cases has been detected in least 5 clusters and from contact tracing, of which 20 were found in two clusters in Perak and Kelantan.
On 12 April 2021 Turkey had 285 cases in 11 provinces.
Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), also known as the coronavirus, is the virus that causes COVID-19, the respiratory illness responsible for the ongoing COVID-19 pandemic. The virus was previously referred to by its provisional name, 2019 novel coronavirus (2019-nCoV), and has also been called human coronavirus 2019. First identified in the city of Wuhan, Hubei, China, the World Health Organization declared the outbreak a Public Health Emergency of International Concern on 30 January 2020, and a pandemic on 11 March 2020. SARS‑CoV‑2 is a positive-sense single-stranded RNA virus that is contagious in humans. As described by the US National Institutes of Health, it is the successor to SARS-CoV-1, the virus that caused the 2002–2004 SARS outbreak.
The COVID-19 pandemic has affected animals directly and indirectly. SARS-CoV-2, the virus that causes COVID-19, is zoonotic, which likely to have originated from animals such as bats and pangolins. Human impact on wildlife and animal habitats may be causing such spillover events to become much more likely. The largest incident to date was the culling of 14 to 17 million mink in Denmark after it was discovered that they were infected with a mutant strain of the virus.
"Cluster 5", also referred to as ΔFVI-spike by the Danish State Serum Institute (SSI), is a variant of SARS-CoV-2, the virus that causes COVID-19, that is believed to be extinct. It was discovered in North Jutland, Denmark, and is believed to have been spread from minks to humans via mink farms. On 4 November 2020, it was announced that the mink population in Denmark would be culled to prevent the possible spread of this mutation and reduce the risk of new mutations happening. A lockdown and travel restrictions were introduced in seven municipalities of North Jutland to prevent the mutation from spreading, which could compromise national or international responses to the COVID-19 pandemic.
The Alpha variant, also known as lineage B.1.1.7, is a variant of SARS-CoV-2, the virus that causes COVID-19. One of several variants of concern, the variant is estimated to be 40–80% more transmissible than the wild-type SARS-CoV-2. It was first detected in November 2020 from a sample taken in September in the United Kingdom, and began to spread quickly by mid-December, around the same time as infections surged. This increase is thought to be at least partly because of one or more mutations in the virus' spike protein. The variant is also notable for having more mutations than normally seen.
The Novavax COVID-19 vaccine, codenamed NVX-CoV2373, is a subunit COVID-19 vaccine candidate developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI), that is undergoing trials in India under the brand name Covovax. It requires two doses and is stable at 2 to 8 °C refrigerated temperatures.
The COVID-19 Genomics UK Consortium (COG-UK) is a group of public health agencies and academic institutions in the United Kingdom created in April 2020 to collect, sequence and analyse genomes of SARS-CoV-2 as part of COVID-19 pandemic response. The consortium comprises the UK's four public health agencies, National Health Service organisations, academic partners and the Wellcome Sanger Institute. The consortium is known for first identifying the SARS-CoV-2 Alpha variant in November 2020. As of January 2021, 45% of all SARS-CoV-2 sequences uploaded to the GISAID sequencing database originated from COG-UK.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), has many variants; some are believed, or have been believed, to be of particular importance due to their potential for increased transmissibility, increased virulence, or reduced effectiveness of vaccines against them.
Gamma variant, also known as lineage P.1, is one of the variants of SARS-CoV-2, the virus that causes COVID-19. This variant of SARS-CoV-2 has been named lineage P.1 and has 17 amino acid substitutions, ten of which are in its spike protein, including these three designated to be of particular concern: N501Y, E484K and K417T. This variant of SARS-CoV-2 was first detected by the National Institute of Infectious Diseases (NIID) of Japan, on 6 January 2021 in four people who had arrived in Tokyo having visited Amazonas, Brazil, four days earlier. It was subsequently declared to be in circulation in Brazil. Under the simplified naming scheme proposed by the World Health Organization, P.1 has been labeled Gamma variant, and is currently considered a variant of concern.
The following is a timeline of the COVID-19 pandemic in the United States during 2021.
Iota variant, also known as lineage B.1.526, is one of the variants of SARS-CoV-2, the virus that causes COVID-19. It was first detected in New York City in November 2020. The variant has appeared with two notable mutations: the E484K spike mutation, which may help the virus evade antibodies, and the S477N mutation, which may help the virus bind more tightly to human cells.
The Delta variant is a new strain of SARS-CoV-2, the virus that causes COVID-19. It was first detected in India in late 2020. The first case of Covid-19 in the United States was diagnosed on January 20, 2020. The Delta variant was named on 31 May 2021 and had spread to over 163 countries by 24 August 2021. The World Health Organization (WHO) indicated that the Delta variant is becoming the dominant strain globally. By the end of January 2020, WHO declared Covid-19 a public health emergency for international concern.
Theta variant, also known as lineage P.3, is one of the variants of SARS-CoV-2, the virus that causes COVID-19. The variant was first identified in the Philippines on February 18, 2021, when two mutations of concern were detected in Central Visayas. It was detected in Japan on March 12, 2021, when a traveler from the Philippines arrived at Narita International Airport in Tokyo.
Kappa variant is a variant of SARS-CoV-2, the virus that causes COVID-19. It is one of the three sublineages of Pango lineage B.1.617. The SARS-CoV-2 Kappa variant is also known as lineage B.1.617.1 and was first detected in India in December 2020. By the end of March 2021, the Kappa sub-variant accounted for more than half of the sequences being submitted from India. On 1 April 2021, it was designated a Variant Under Investigation (VUI-21APR-01) by Public Health England.
Lineage B.1.617 is a lineage of SARS-CoV-2, the virus that causes COVID-19. It first came to international attention in late March 2021 after the newly established INSACOG performed genome sequencing on positive samples throughout various Indian states. Analysis of samples from Maharashtra had revealed that compared to December 2020, there was an increase in the fraction of samples with the E484Q and L452R mutations. Lineage B.1.617 later came to be dubbed a double mutant by news media.
Lambda variant, also known as lineage C.37, is a variant of SARS-CoV-2, the virus that causes COVID-19. It was first detected in Peru in August 2020. On 14 June 2021, the World Health Organization (WHO) named it Lambda variant and designated it as a variant of interest. It has spread to at least 30 countries around the world and is known to be more resistant to neutralizing antibodies compared to other strains. There is evidence that suggests the Lambda variant is both more infectious and resistant to vaccines than the Alpha and/or Gamma variant.
Epsilon variant, also known as CAL.20C and referring to two PANGO lineages B.1.427 and B.1.429, is one of the variants of SARS-CoV-2, the virus that causes COVID-19. It was first detected in California, USA in July 2020.
Zeta variant, also known as lineage P.2, is a variant of SARS-CoV-2, the virus that causes COVID-19. It was first detected in the state of Rio de Janeiro; it harbors the E484K mutation, but not the N501Y and K417T mutations. It evolved independently in Rio de Janeiro without being directly related to the Gamma variant from Manaus.
The Eta variant is a variant of SARS-CoV-2, the virus that causes COVID-19. The Eta variant or lineage B.1.525, also called VUI-21FEB-03 by Public Health England (PHE) and formerly known as UK1188, 21D or 20A/S:484K, does not carry the same N501Y mutation found in Alpha, Beta and Gamma, but carries the same E484K-mutation as found in the Gamma, Zeta, and Beta variants, and also carries the same ΔH69/ΔV70 deletion as found in Alpha, N439K variant and Y453F variant.
COVID-19 vaccine clinical research is the clinical research on COVID-19 vaccines, including their efficacy, effectiveness and safety. There are 22 vaccines authorized for use by national governments, with six vaccines being approved for emergency or full use by at least one WHO-recognised stringent regulatory authority; and five of them are in Phase IV. 204 vaccines under clinical trials that have not yet been authorized. There are also nine clinical trials on heterologous vaccination courses.
The Mu variant, also known as lineage B.1.621 or VUI-21JUL-1, is one of the variants of SARS-CoV-2, the virus that causes COVID-19. It was first detected in Colombia in January 2021 and was designated by the WHO as a variant of interest on August 30, 2021. The WHO said the variant has mutations that indicate a risk of resistance to the current vaccines and stressed that further studies were needed to better understand it. Outbreaks of the Mu variant were reported in South America and Europe. The B.1.621 lineage has a sublineage, labeled B.1.621.1 under the PANGO nomenclature, which has already been detected in more than 20 countries worldwide.
N501Y...has been found in other countries, including the United Kingdom
Spatiotemporal phylogeographic analysis suggests that the 501Y.V2 lineage emerged in early August (early July – end August 2020, 95% highest posterior density) in Nelson Mandela Bay.
I should note here that there’s another strain in South Africa that is bringing on similar concerns. This one has eight mutations in the Spike protein, with three of them (K417N, E484K and N501Y) that may have some functional role.
The South African variant ‘501.V2’ is characterised by N501Y, E484K and K417N mutations in the S protein – so it shares the N501Y mutation with the UK variant, but the other two mutations are not found in the UK variant. Similarly, the South African variant does not contain the 69-70del mutation that is found in the UK variant.
Chief among those is another receptor-binding-domain mutation, called E484K, that de Oliveira’s team has identified in the 501Y.V2 variant.
South Africa will suspend use of the coronavirus vaccine being developed by Oxford University and AstraZeneca after researchers found it provided "minimal protection" against mild to moderate coronavirus infections caused by the new variant first detected in that country.
Our clinicians have also warned us that things have changed and that younger, previously healthy people are now becoming very sick.
This variant was first observed in samples from October, and since then more than 300 cases with the 501.V2 variant have been confirmed by whole genome sequencing (WGS) in South Africa
...the new strain of the COVID-19 virus, known as 501V2 variant, has been detected in Botswana.
Mittlerweile gebe es sechs Virusnachweise bei sechs Personen aus drei Haushalten, teilte das Ministerium mit. (There are now six virus detections in six people from three households, the ministry said.)
Scientists are particularly concerned about the South African variant, named B1351... ...At least 29 cases in the UK and three in Ireland have been recorded.
There are 20 known cases of the variant in the country that resulted from seven chains of infection.
Verder zijn er inmiddels drie gevallen van de Zuid-Afrikaanse variant bekend, een andere besmettelijke mutatie van het coronavirus. (Furthermore, three cases of the South African variant, another contagious mutation of the coronavirus, are now known.)
Another 444 individuals have been found to be carrying the South African variant.
Another 444 individuals have been found to be carrying the South African variant.